- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Varian to purchase GE's radiotherapy unit
Varian Associates has offered to purchase the radiotherapy service and support operation of GE Medical Systems in a deal that will cover all of the Milwaukee vendor's worldwide radiotherapy service and customer support operations. GEMS has a global
Varian Associates has offered to purchase the radiotherapy service and support operation of GE Medical Systems in a deal that will cover all of the Milwaukee vendor's worldwide radiotherapy service and customer support operations. GEMS has a global installed base of 400 linear accelerator systems and some 340 treatment planning products, according to the companies. The sale does not include GE's radiotherapy manufacturing and engineering unit located in Buc, France, which is under review, according to GEMS.
The purchase, for an undisclosed amount of cash, is expected to be completed by the end of 1997. About 160 GEMS radiotherapy service professionals, technical support personnel, and support staff will join Varian on completion of the transaction. Varian executives said that the acquisition significantly broadens the Palo Alto, CA-based company's international radiotherapy support. For GEMS, the deal allows the vendor to focus more closely on its core medical imaging, services, and information technology businesses, according to Jeffrey Immelt, president and CEO.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
